News

1722 news items

Research

Better known risks of Zolgensma

On 04/10/2021

Zolgensma® (onasemnogene abeparvovec) is the first gene therapy product to obtain marketing authorization in 2019 in a neuromuscular disease, namely SMA.  Various serious side effects…

Research

Sexual dysfunction more common in myasthenia gravis

On 23/09/2021

Sexual dysfunction includes problems related to sexual activity: libido, stimulation, painful intercourse, reduced satisfaction and orgasmic disorders, etc. A Chinese observational study evaluated the frequency…